The utility of a risk function in clinical practice is an important concept that has received insufficient attention. The authors evaluated the clinical usefulness of the Framingham risk function (FRF) for cardiovascular disease in a Middle Eastern population (2,640 men and 3,584 women aged 30-74 years) free of cardiovascular disease at baseline in 1999. They calculated the net benefit fraction for treatment of subjects with an estimated 10-year risk of ≥10% and also ≥20%, where the net benefit fraction is a weighted sum of true-positive and false-positive rates divided by incidence, as estimated by Kaplan-Meier analysis. The authors drew a decision curve by plotting the net benefit fraction against a wide range of risk thresholds for treatment. The cumulative incidence of cardiovascular disease was 7.6% and 12.3% in women and men, respectively. The FRF had a C index of 0.832 in women and 0.785 in men with a reasonable calibration. On the basis of the net benefit fraction, about 50% of the incidence in men and women could be appropriately treated by using the 10% threshold; however, the FRF was not useful at the 20% threshold, especially in women. In both genders, usefulness of the FRF was as good as the function derived directly from Tehrani data with the same variables; however, it could be useful in low thresholds for treatment.
uncertainties, patient (or physician) preferences, and costs. Subsequently, there are sometimes conflicting decisions based on the harm and benefit of a treatment (18) . Vickers and Elkin (15) and Vickers et al. (16) propose decision curve analysis as an approach to quantify the clinical usefulness of a prediction model considering a range of harm/ benefit ratios according to the probability of disease at which a patient would opt for treatment (15, 16) .
In an Iranian population with a high prevalence of coronary heart disease and its risk factors (19, 20) , we evaluated the accuracy and the clinical importance of the last version of the FRF, a general cardiovascular risk profile for use in the primary care setting (8) . The 5-year predictive ability of this algorithm has been examined earlier in the Tehran Lipid and Glucose Study population (12) . Nevertheless, in this study we aimed to consider the 10-year predictive ability, based on the original FRF which uses 10-year risk (8) . More importantly, we intended to evaluate the clinical usefulness of this risk function using decision curve analysis (15, 21) that, to the best of our knowledge, has not been considered previously by FRF validation studies (10) (11) (12) (13) .
MATERIALS AND METHODS

Study population
The Tehran Lipid and Glucose Study (TLGS) is a population-based cohort study to determine the risk factors for noncommunicable diseases among a population of Iran's capital city, Tehran; the study methods have been described elsewhere (19, 22) . Briefly, a total of 15,005 individuals, aged 30 years or more, were selected from district 13 of Tehran. They were assigned to intervention and nonintervention categories, the former to be educated for implementation of lifestyle modifications. There were 7,907 individuals, aged 30-74 years, who participated in the baseline phase; we excluded subjects who had a history of cardiovascular disease (n = 487), missing data (n = 208), or were lost to follow-up (n = 988). The remaining 6,224 subjects (2,640 men and 3,584 women), representing 84% of those eligible, underwent final analysis. Participants entered the study in 1999 and were followed up until 2009, with a median follow-up of 9.3 years. Written, informed consent was obtained from all subjects, and the study was approved by the ethics committee of the Research Institute for Endocrine Sciences.
Measurements
Measurements of demographic and clinical characteristics, physical examinations, and laboratory tests at baseline have been described before (19) . Potential explanatory factors used in the present study include sex, age, hypertension medication, diabetes medication, smoking, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol, and fasting plasma glucose. Diabetes mellitus was defined as individuals with fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL) or a history of glucose-lowering medications; smoking was defined as a history of current (daily or occasional) smoking. Outcome measurements have been described elsewhere (22) . In the current study, we considered a cardiovascular disease event as any coronary heart disease event, that is, myocardial infarction, unstable angina pectoris, angiographically proven coronary heart disease (including those with symptoms of stable angina), and coronary heart disease death, heart failure, and cerebrovascular events (ischemic or hemorrhagic stroke, transient ischemic attack, and cerebrovascular death).
Statistics
Characteristics of study subjects were shown as the mean (standard deviation) or as percentages for the TLGS population versus the Framingham population. Sex-specific Cox proportional hazard models were derived after checking the assumption of proportionality. For each component of the Framingham general cardiovascular disease risk profile (age, total cholesterol, high density lipoprotein cholesterol, systolic blood pressure in treated and nontreated individuals for hypertension, smoking, and diabetes), the hazard ratios in the TLGS and Framingham cohorts were compared by using a 2-tailed z statistic (23) .
We used Harrell's concordance statistic (C index) and a modified version of Hosmer-Lemeshow's χ 2 , as discussed by D'Agostino and Nam (24) , to evaluate discrimination and calibration of model predictions, respectively (17) . We also used the R 2 statistic of Royston (25) as a measure of explained variation for survival models indicating overall performance of the model (17, 25) . To show the calibration in more detail, we drew the observed versus the predicted probabilities in deciles of predicted probability (23) . We evaluated the clinical usefulness of the models as well (15, 17, 21, 26) . To do this, we classified subjects with predictions above a defined threshold as positive (high risk) and those under the threshold as negative. We compared this classification with observed cardiovascular diseases during the 10-year follow-up and identified the numbers as true positive (TP), false positive (FP), true negative (TN), and false negative (FN). To calculate the sensitivity, specificity, and net benefit of models, we used the threshold of 20%, which is the threshold for high global cardiovascular disease risk according to D'Agostino et al. (8) and needs more aggressive risk factor modification as presented by Marma and Lloyd-Jones (8, 27) , and the threshold of 10% to consider moderate risks as well (28, 29) .
Net benefit is defined as (TP − w × FP)/N, where TP is the number of true-positive decisions, FP is the number of false-positive decisions, N is the total number of the population, and w is a weight equal to the odds of the threshold (P treatment /(1 − P treatment )), which is considered as the harm/ benefit ratio of treatment; for example, at the threshold of 10%, the FP is valued at one-ninth of the TP (21) . Because the maximum net benefit equals the incidence rate of disease (15) , given that all events are TP with no FP, we divided net benefit by the incidence rate. In this way, we defined the net benefit fraction as a simple relative utility index (30) , which is the fraction of the incidence rate that could be predicted and prevented, appropriately regarding the usefulness of treatment for true positives and a negative weight for harmfulness of treatment in false positives. To draw a decision curve, we considered distribution of the net benefit fraction across a wide range of thresholds for treatment (15) .
To calculate TP, TN, FP, and FN in censored data, we first applied the Kaplan-Meier estimator to compute "observed probability" and the models to compute "predicted probability" for 10 years of follow-up. Then, we considered S(t) as Kaplan-Meier survival probability, x = 1 if "predicted probability" ≥ P treatment (threshold), and x = 0 otherwise. Now, TP is defined as {1 -[S(t)|x = 1]} × P(x = 1) × N, TN as [S(t)|x = 0] × P(x = 0) × N, FP as [S(t)|x = 1] × P(x = 1) × N, and FN as {1 -[S(t)|x = 0]} × P(x = 0) × N, where N is the total number of the population. The assumption is that censoring is independent of the predictors of the model (16) .
We calculated discrimination, calibration, and clinical usefulness indices for 3 models: the "original Framingham," the "recalibrated Framingham," and the "TLGS refitted Framingham." To estimate prediction based on the original Framingham model, we calculated the 10-year probability of a cardiovascular disease event for everyone in the TLGS regarding his/her individual risk factors but applying regression coefficients, baseline survival, and mean values of the original Framingham model. We recalibrated the Framingham cardiovascular disease risk function according to the TLGS cohort characteristics using the method described by previous studies (31, 32) ; that is, we recalculated the 10-year probability of a cardiovascular disease event for everyone in the TLGS with respect to his/ her own risk factors, baseline survival, and mean values of the TLGS and using regression coefficients from the Framingham model. We recomputed the calibration and clinical usefulness of the FRF after recalibration, bearing in mind that recalibration does not change the discrimination of the model. We finally refitted the FRF with the TLGS; that is, we reestimated the regression coefficients to obtain the best fit to the TLGS cohort. In this way, the probability of an event was calculated for everyone by using individual risk factors and regression coefficients, baseline survival, and mean values of the TLGS.
Statistical analyses were performed by using SPSS for Windows, version 15 (SPSS, Inc., Chicago, Illinois), and Stata, version 10 (StataCorp LP, College Station, Texas), statistical software. Two-sided P < 0.05 was considered statistically significant. Table 1 . The TLGS women were younger and had lower levels of high density lipoprotein cholesterol, a lower smoking rate, and higher diabetes prevalence, and the men had lower levels of high density lipoprotein cholesterol, a lower systolic blood pressure, and a lower rate of treatment for hypertension compared with the women and men in the Framingham cohort, respectively. A total of 515 cardiovascular disease events, including coronary heart disease (n = 195 and 242), cerebrovascular events (n = 24 and 43), and congestive heart failure (n = 7 and 4), occurred in women and men, respectively, during the 10 years of follow-up. The Kaplan-Meier failure rate of cardiovascular disease was 7.6% and 12.3% in women and men, respectively. The hazard ratios of cardiovascular disease for risk factors of the Framingham function versus the corresponding hazard ratios in the TLGS study are shown in Table 2 . The results showed that systolic blood pressure among the TLGS women is not as important a risk factor as it is among Framingham women. The hazard ratios for risk factors in the TLGS cohort were reestimated in the group not assigned to the intervention; the differences were negligible (Web Table 1 , the first of 4 Web tables and 3 Web figures available at http://aje.oxfordjournals.org/). In both genders, the log-rank test showed no significant difference in survival experience between the intervention and nonintervention groups (P = 0.97 and 0.56 for women and men, respectively); thus, to increase our statistical power, we kept the whole study population in our final analysis. Table 3 shows a summary of statistics for model performance. In both genders, the R 2 statistic and the C index are nearly the same in the Framingham and TLGS models. The discrimination power in women was higher than that in men (83.2% vs. 78.5% based on the FRF). All 3 models in women were reasonable but not well calibrated, whereas in men the TLGS and recalibrated Framingham models were well calibrated. Figure 1 shows the calibration of models in more detail. In women, the predicted probabilities of all 3 models were similar to the observed risks in the high predicted-risk category but, in intermediate categories, the predicted probabilities underestimated the risk. In men, the original Framingham model generally overestimated the risk except in intermediate categories, where the predicted risks agreed well with the observed risks. The agreement of observed and predicted risks was better in recalibrated and TLGSrefitted Framingham models with some underestimation in intermediate predicted risks. Table 4 shows the clinical performance of the models based on the 2 thresholds of 10% and 20%. In women and men, the sensitivity and net benefit fraction of the original, recalibrated, and TLGS-refitted Framingham models were very low at the cutpoint of 20%. Considering the cutpoint of 10%, men had a better sensitivity but lower specificity than did women. However, the net benefit was about 50% 
RESULTS
Characteristics of the TLGS and Framingham populations have been summarized in
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Am J Epidemiol. 2012;176(3):177-186 of the incidence for both genders. Sensitivity of the original Framingham model was better than those of the recalibrated and refitted TLGS models at the threshold of 20% (66% vs. 56%). However, all models had nearly the same net benefit fraction (29%-32%). On the basis of decision curve analysis (Figure 2 ), in both genders, all 3 models had nearly the same net benefit fraction in nearly all thresholds. Among women and in the thresholds around 10%-15%, the curves are farther away from the "treat none" and "treat all" lines, indicating more benefit for giving treatment based on the model instead of treating all or treating none of the individuals. The corresponding thresholds for men were 15%-20%.
DISCUSSION
This study investigated the predictive performance of the Framingham general cardiovascular risk profile (8) in a Middle Eastern population considering different aspects including discrimination, calibration, and clinical usefulness, the last one having been ignored in previous similar studies (10) . We found that the FRF had good power to discriminate low-and high-risk people; however, it does not lead to good clinical usefulness at high cutpoints, such as 20%, that were considered for more aggressive risk factor modification (8) . We also compared the original FRF and the FRF recalibrated for the TLGS cohort with the function derived from the TLGS cohort (based on Framingham covariates) and found that they are not so different in predicting cardiovascular disease events and that all of them have similar shortcomings, especially in women.
Recalibration did not improve the FRF performance in our women as we expected. Recalibration is the first step of updating a prediction model for a new setting (21) . The assumption for recalibration is that the nature and strengths of the associations between risk factors and cardiovascular disease are constant across populations, and recalibration just modifies the equation for risk factor distributions and background incidence of cardiovascular disease in the new setting (31, 33) . We did recalibration because of differences between these parameters in the TLGS and Framingham populations. Recalibration caused a well-calibrated Framingham model in men but did not perform well in women because of different associations between some of the risk factors, especially systolic blood pressure, and cardiovascular disease in the TLGS compared with Framingham women. On the other hand, the TLGS prediction model with selected covariates, which are components of the FRF, lacked good calibration. These findings demonstrate that we need other steps in updating, for example, model revision and model extension, namely, reestimating some parameters in the model (new coefficients) and considering additional predictors for women in the population (21) . For example, central obesity is an independent risk factor for cardiovascular disease events in the TLGS women (34) that can be used as an additional covariate in the FRF to improve the model. We did so and found a better calibration for the model: Hosmer-Lemeshow χ 2 of 26.8 for the model including the waist/hip ratio versus 37.5 for the model without it (data not shown). The other reason for this low performance in women could be the low incidence rate for them. The cumulative incidence rate in women is 7.6% versus 12.3% in men. The average age for the TLGS women is 46.2 years, which is below the age of menopause and can explain the low incidence rate of cardiovascular disease, whereas this mean age is 49.1 in Framingham women (8) . The net benefit fraction equals the fraction of incidence that would be predicted and prevented appropriately regarding the usefulness of treatment in true positives and a negative weight for the harmfulness of treatment in false positives.
Recently, we showed that aging decreases the effect of systolic blood pressure on cardiovascular disease incidence (35) . We checked this matter in current data and found that there is a serious interaction between systolic blood pressure and age in women. For example, the risk of a 10-mm Hg increase in systolic blood pressure decreases about 4% after the age of 60 years (P = 0.007) (data available on request). Because most of the events occur at older ages and after menopause, this matter reduces the risk of systolic blood pressure for cardiovascular disease events in women. That is, among an older population with other coexisting comorbidities, cardiovascular disease outcomes occurred in the presence of high or even normal blood pressure. In contrast with our data, Framingham Study data showed that with increasing age, there is a gradual shift from diastolic to systolic blood pressure as predictors of coronary heart disease (36) . This may explain the significant differences between hazard ratios of systolic blood pressure in these 2 populations.
Regarding discrimination and calibration, there are similarities and differences between the findings from our study and those from the existing literature. It has been shown that the FRF achieved good calibration in populations from the United States, Australia, and New Zealand, but it overestimated the risk in Europeans and requires adjustment (10) . An adaptation of the FRF for coronary heart disease in European Mediterranean areas showed that, after recalibration, the estimated/observed ratio was close to 1.0 in men but still above 1.0 for women (31) . Recalibration of the FRF in a Swiss population led to a reasonable coronary heart disease risk prediction in men but not in women (11) . In a rural population of India, the original and recalibrated FRFs were directly comparable (33), which is different from those observed in other parts of Asia, where the original FRF typically overestimates risk levels (32, 37). The 5-year predictive ability of Framingham's general cardiovascular disease algorithm in the TLGS population showed that the FRF is well calibrated in the TLGS population in both genders (12) . Comparing these results with those from the present study reflects the role of the regression dilution bias that may be a result of changes in baseline variables over time and that eventually dilutes the associations of predictors with outcome (21) . However, longer follow-up can reflect the effect of exposures better because some causal relations need long induction periods (38) .
We used sensitivity, specificity, net benefit fraction, and the decision curve analysis approach to measure clinical usefulness of the risk functions and to finalize our evaluation. Few studies have used sensitivity and specificity to assess the performance of cardiovascular risk equations. Koller et al. (39) in the Rotterdam Study evaluated the Framingham point scores for validity in the elderly. They found a high false-negative rate (subsequently low sensitivity) in women when examining the high-risk decision rule for case finding as recommended by the Adult Treatment Panel III. Similarly, in our study, the sensitivity of prediction was lower in high cutpoints compared with low cutpoints and especially in women with a low incidence rate. As for the net benefit fraction, in women and at the 20% threshold, only 15% of the incidence rate of cardiovascular disease would be predicted and treated correctly on the basis of the models; in men, this is 30%, so we would gain little by using this threshold. However, the threshold of 10% seems a good cutpoint at which to consider high-risk individuals for treatment; about 50% of cardiovascular disease events in men and women would be predicted and treated appropriately with application of the 10% threshold.
Because there are some differences in guidelines for treatment of diabetic and nondiabetic individuals (40), we applied the decision curve for these subgroups separately (Web Figures 1 and 2 ). We found that there is no difference between the "treat all" and "treat based on model" approaches in diabetic patients through a wide range of thresholds. The "treat all" approach may even be better for women in the thresholds of 15%-20% (Web Figure 1) . It is because more people are in the high-risk categories in the diabetic subgroup than in the general population (Web Tables 2 and 3 ). On the other hand, the risk of cardiovascular disease in diabetic patients is similar to that of patients with prior coronary heart disease, and all of them should be treated according to guidelines (5, 41) . This observation agrees with our previous results that risks from diabetes and coronary heart disease are equivalent, and all subjects should receive intensive, primary preventive treatment for cardiovascular disease regardless of risk factors (42, 43) . On the basis of the decision curve in the nondiabetic subgroup (Web Figure 2) , the appropriate thresholds are around 10% in women and 15% in men. The net benefit was about zero at the 20% cutpoint (Web Table 4 ). Recently, Murphy et al. (44) showed that the conventional 20% cutoff for 10-year risk of hard coronary heart disease is not suitable when treating nondiabetic subjects and recommended lower cutpoints, even as low as 5%. They used a receiver operating characteristic curve to point out that lowering the threshold results in substantial increases in sensitivity, with much smaller losses in specificity. However, the receiver operating characteristic curve cannot make a distinction between the importance of sensitivity and "1 − specificity" (subsequently TP and FP), the point that is considered in the net benefit formula and the decision curve. Part of the difference in results between those of Murphy et al. and our own is due to different outcomes: They studied hard coronary heart disease as the outcome, while we used total cardiovascular diseases as the outcome. When we drew the decision curve for only coronary heart disease events instead of cardiovascular disease, the results did not change dramatically, but suitable thresholds slightly decreased (data are available on request). This is because more than 85% of our events were diagnosed as coronary heart disease.
The comparison of sensitivity and the net benefit fraction shows some important points. In our male subjects, the sensitivity of the Framingham model at the threshold of 10% was 85% (Table 4 ), indicating that using this risk function, we would identify 85% of future cardiovascular disease events. Nonetheless, according to the net benefit fraction, we would treat only about 50% of future cardiovascular disease cases reasonably, because of considering the negative weight for treating false positives in the net benefit formula. The lower weight for treating false positives (i.e., generating cheaper drugs with lower side effects) accounts for the smaller difference between these indices. The net benefit fraction, like sensitivity, does not depend on the incidence of disease. This is an advantage over the net benefit. So, the net benefit fraction can be compared across populations, irrespective of the incidence of the disease. For instance, regarding the net benefit of the FRF, there was much more benefit for men than for women through a wide range of thresholds, but in regard to the net benefit fraction, the FRF was better in men only in the range of 15%-30% (Web Figure 3) . Now we can say that the performance of the FRF is better in men than women in view of some of the thresholds used in clinical practice.
We believe that decision curve analysis should not be used instead of cost-effectiveness studies. However, the former could determine the performance of clinical risk functions in a varied range of cost-benefit thresholds that may be preferred, depending on the cost of treatment and how much people are willing to pay for better health outcomes (45) . On the other hand, subgroup variations in the side effects of interventions may influence the ratio of harm to benefit in individual patients and the cost-effectiveness of preventive interventions (46) . As a result, decision curve analysis could help clinicians to find out whether the reasonable (costbenefit) thresholds based on the patient's condition are matched with the suitable thresholds based on the model. If they are, then the model could be clinically useful.
An advantage of our study, which clinically evaluated a well-known cardiovascular disease risk function, is that it includes a population-based cohort representing an urban population in Iran (22) , but extending the results to the entire population, especially to rural individuals, should be done carefully. We used 2 thresholds of 20% and 10% as examples by which to evaluate the models clinically. Nevertheless, we could evaluate the performance of the models using decision curve analysis in a wide range of thresholds. It should be kept in mind that functions are not used by solely selecting a cutoff point. As a limitation, our study outcomes cover Framingham Study cardiovascular disease events except for intermittent claudication and silent myocardial infarction, leading to underestimation of cardiovascular disease events. However, this might not affect our results because less than 15% of cardiovascular disease events in the Framingham Study have been due to intermittent claudication, overlapping with other cardiovascular disease events (47) , and about 12% of acute myocardial infarctions were completely silent (48) .
In conclusion, the Framingham General Cardiovascular Risk Profile can be used as a screening tool in primary care to prevent cardiovascular disease in Iranian subjects, with more usefulness in men, despite better discrimination power in women. In both genders, the FRF acts as effectively as the function derived from Tehrani data using the same variables, although it could be useful in low thresholds for treatment. Because of the same shortcomings for women in both the original and the TLGS-refitted Framingham models, additional studies on risk function including common risk factors are recommended for women.
